Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors

NCT ID: NCT03385486

Last Updated: 2022-05-03

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-06-02
• Study Completion Date: 2024-12-31

Brief Summary

This is a study of transfusion of TBX-3400 in patients with stage III and IV melanoma resistant or refractory to Immune Checkpoint Inhibitors.

The patient's own blood cells are exposed to a protein that has been shown in the laboratory to result in anti-tumor activity.

The study hypothesis is that TBX-3400 cells will enhance anti-tumor activity and improve the body's immune response.

Conditions

Stage III Melanoma; Stage IV Melanoma

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TBX-3400

TBX-3400 by intravenous infusion

Group Type: EXPERIMENTAL

TBX-3400

Intervention Type: BIOLOGICAL

Autologous transfusion

Interventions

TBX-3400

Autologous transfusion

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Histopathologically confirmed diagnosis of advanced, unresectable or metastatic malignant melanoma

2. Male or female patients age 18 or older

3. Previously treated with checkpoint inhibitor therapy either alone or in combination with either stable disease or progressive disease per RECIST version 1.1 (there is no minimum treatment duration for patients who have progressive disease while on checkpoint inhibitor therapy)

4. Measurable or evaluable disease by RECIST version 1.1

5. Capable of understanding and complying with protocol requirements

6. A life expectancy of greater than 24 weeks at Screening

7. ECOG Performance Status of 0 to 2

8. Written informed consent from the patient or the patient's legally acceptable representative prior to the initiation of any study procedures

9. Adequate bone marrow, liver, and renal function as defined below:

• hemoglobin ≥8.0 g/dL (transfusions allowed)
• absolute neutrophil count ≥1500/µL
• platelet count ≥100,000/µL (transfusions allowed)
• alanine transaminase and aspartate transaminase ≤3.0 times the upper limit of normal (ULN), or ≤5 times ULN for patients with known hepatic metastases
• total serum bilirubin ≤1.5 x the ULN; ≤2.0 x the ULN if liver metastases are present; patients with a known history of Gilbert's syndrome (≤3.0 x the ULN) and/or isolated elevations of indirect bilirubin are eligible for study participation
• estimated glomerular filtration rate ≥50 mL/min/1.73 m^2 (using Cockcroft Gault formula)

Exclusion Criteria

Patients who meet any of the following criteria will not be eligible for participation in the study:

1. Pregnant or breast feeding

2. Developed immune-related toxicity while on prior checkpoint inhibitor therapy that has not yet returned to Grade 1 or better

3. Require systemic pharmacologic doses of corticosteroids at or above the equivalent of 10 mg/day of prednisone; replacement doses, topical, ophthalmologic and inhalational steroids are permitted

4. Active, symptomatic central nervous system (CNS) metastases. Patients with CNS metastases are eligible for the trial if the metastases have been treated by surgery and/or radiotherapy and the patient is off corticosteroids and is neurologically stable for at least 7 days prior to screening

5. Any concurrent uncontrolled illness, including mental illness or substance abuse which in the opinion of the investigator would make the patient unable to cooperate or participate in the trial

6. Severe uncontrolled cardiac disease within 3 months of study entry, including unstable or new onset angina, myocardial infarction or cerebrovascular accident

7. Women of childbearing potential who are unable or unwilling to use an acceptable method of contraception

8. Known infection with human immunodeficiency virus (HIV) that is not well controlled on anti-retroviral therapy as defined by HIV RNA more than 400 copies/mL or severely symptomatic

9. Presence of Hepatitis B and/or Hepatitis C active infection

10. Symptomatic congestive heart failure, defined as New York Heart Association Class II or higher

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Taiga Biotechnologies, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

The Angeles Clinic and Research Institute

Los Angeles, California, United States

Site Status: RECRUITING

University of Colorado Cancer Center

Denver, Colorado, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Yosef Refaeli, PhD

Role: CONTACT

refaeli@taigabiotech.com

+1-720-859-3547

Vivienne Margolis

Role: CONTACT

vmargolis@taigabiotech.com

+972-52-463-9634

Facility Contacts

Dr. Inderjit Mehmi, MD

Role: primary

imehmi@theangelesclinic.org

310-294-0438

Theresa Medina, MD

Role: primary

Theresa.Medina@ucdenver.edu

720-848-7135

Other Identifiers

TBX-3400-001

Identifier Type: -

Identifier Source: org_study_id